Back to top

Analyst Blog

UCB (UCBJF) recently reported results for the first quarter of 2013. Revenues fell 8.2% year over year to approximately $1.1 billion due to generic erosion of Keppra and a delayed allergy season.

All growth rates mentioned below are on a year-on-year basis and at CER.

While Cimzia (Crohn’s disease and rheumatoid arthritis) sales increased 27% in the reported quarter, Vimpat (epilepsy) sales increased 16%. Neupro, which is marketed as a treatment for Parkinson’s disease (PD) and restless legs syndrome (RLS), delivered sales growth of 37%.

However, sales of Keppra, another epilepsy treatment, declined 22%. Sales were hurt by generic competition in the US and Europe.

Pipeline Update

Vimpat as monotherapy met its primary endpoint in a phase III study on epilepsy in the US. The company intends to file for US approval in the second half of 2013.

For the PD and RLS indications, Neupro received regulatory approval in Japan in Dec 2012. UCB’s partner, Otsuka Pharmaceuticals, has launched Neupro in Japan.

For the RA indication, Cimzia was approved in Japan in Dec 2012. UCB’s partner Astellas Pharma, Inc. (ALPMY) has launched the drug in Japan.

UCB is currently looking to get Cimzia’s label expanded for the treatment of active psoriatic arthritis and active axial spondyloarthritis in the US, EU and other regions.

.2013 Guidance

The company maintained its previously issued guidance of €3.4 million of revenues for 2013 and earnings per share in the band of €1.90–€2.05.

UCB carries a Zacks Rank #1 (Strong Buy). Other companies like Catalyst Pharmaceutical Partners Inc. (CPRX - Snapshot Report) and Onyx Pharmaceuticals, Inc. also carry a Zacks Rank #1.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 2.99 +2.75%
CHIPOTLE ME… CMG 689.85 +1.69%
CHINA BIOLO… CBPO 46.80 +1.60%
ILLUMINA IN… ILMN 174.67 +0.99%
GILEAD SCIE… GILD 101.68 +0.88%